obesity treatment with bariatric surgery vs glp-1 receptor agonists Drugs vs. Bariatric Surgery vs. GLP-1 Medications:
Description
It enrolled 17,604 adults aged 45 or older with a body mass index (BMI) of 27 kg/m2 or greater and preexisting CVD (prior MI, prior stroke or peripheral artery disease) without diabetes
The literature review includes articles published when the terminology of MASLD was referred to as NAFLD (Nonalcoholic fatty liver disease)
Frontiers in endocrinology
Regional Insights North America was the largest region in the GLP-1 receptor agonist market in 2025
[DOI] [PubMed] [Google Scholar] 25.Jendle J., Grunberger G., Blevins T., Giorgino F., Hietpas R
